Department of Radiobiology and Molecular Genetics,
VINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia,
University of Belgrade
, Belgrade
, Serbia
Department of Radiobiology and Molecular Genetics,
VINČA Institute of Nuclear Sciences - National Institute of the Republic of Serbia,
University of Belgrade
, Belgrade
, Serbia
We are the witnesses of a significant increase in chronic kidney diseases (CKD) occurrence. There is scarce literature evidence about functional integrity and natural adaptation of endocrine system axes in patients with different stages of always progressive CKD. Such a problem is growing with the beginning of renal replacement treatments (peritoneal and hemodialysis) or even with renal transplantation. The close monitoring of CKD patients by nephrologist and endocrinologist is mandatory because the natural adaptation of the endocrine system in CKD patients must be differed out of endocrine dysfunction, which has to be treated. Endocrine dysfunction management principles are mostly the same as for the patients with no CKD, except for close drug dose monitoring, especially in the circumstances with concomitant renal replacement treatment.
Xu LG, Xu HM, Zhu XF, Jin LM, Xu B, Wu Y, et al. Examination of the semen quality of patients with uraemia and renal transplant recipients in comparison with a control group. Andrologia. 41(4):235–40.
2.
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016;26(10):1343-1421.
3.
N’Gankam V, Uehlinger D, Dick B, Frey BM, Frey FJ. Increased cortisol metabolites and reduced activity of 11β-hydroxysteroid dehydrogenase in patients on hemodialysis. Kidney International. 61(5):1859–66.
4.
Arregger AL, Cardoso EM, Tumilasci O, Contreras LN. Diagnostic value of salivary cortisol in end stage renal disease. Steroids. 73(1):77–82.
5.
H R, H T. Circadian rhythm of salivary cortisol, plasma cortisol, and plasma ACTH in end-stage renal disease. Endocr Connect. 2(1):23–31.
6.
Perogamvros I, Keevil BG, Ray DW, Trainer PJ. Salivary Cortisone Is a Potential Biomarker for Serum Free Cortisol. The Journal of Clinical Endocrinology & Metabolism. 95(11):4951–8.
7.
Contreras LN, Arregger AL, Persi GG, Gonzalez NS, Cardoso EM. A new less-invasive and more informative low-dose ACTH test: salivary steroids in response to intramuscular corticotrophin. Clin Endocrinol (Oxf. 61(6):675–82.
8.
Carroll T, Raff H, Findling J. Late-night salivary cortisol for the diagnosis of Cushing’s syndrome: a meta-analysis. Endocrine Practice. 15:335–42.
9.
Drechsler C, Ritz E, Tomaschitz A, Pilz S, Schönfeld S, Blouin K, et al. Aldosterone and cortisol affect the risk of sudden cardiac death in haemodialysis patients. European heart journal. 34(8):578–87.
10.
Arregger AL, Cardoso EM, Zucchini A, Aguirre EC, Elbert A, Contreras LN. Adrenocortical function in hypotensive patients with end stage renal disease. Steroids. 84:57–63.
11.
Gungor O, Kircelli F, Carrero JJ, Asci G, Toz H, Tatar E, et al. Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging? Clinical journal of the American Society of Nephrology : CJASN. 5(11):2018–23.
12.
Eps C, C H, J J, DW J, S C, N I, et al. Changes in serum prolactin, sex hormones and thyroid function with alternate nightly nocturnal home haemodialysis. Nephrology (Carlton. 17(1):42–7.
13.
A-f A, M S, A D, N M, A S, A F. Erectile function and gonadal hormones levels in men with end-stage renal disease: It’s relevance to duration of haemodialysis. Andrologia. 50(8).
14.
Lim VS. Thyroid function in patients with chronic renal failure. American Journal of Kidney Diseases. 38(4, Supplement).
15.
Prem AR, Punekar SV, Kalpana M, Kelkar AR, Acharya VN. Male reproductive function in uraemia: efficacy of haemodialysis and renal transplantation. Br J Urol. 78(4):635–8.
16.
M L, B H. Semen quality in men with chronic kidney disease and its correlation with chronic kidney disease stages. Andrologia. 47(10):1103–8.
17.
Eckersten D, Giwercman A, Pihlsgård M, Bruun L, Christensson A. Impact of Kidney Transplantation on Reproductive Hormone Levels in Males: A Longitudinal Study. Nephron. 138(3):192–201.
18.
Reinhardt W, Kübber H, Dolff S, Benson S, Führer D, Tan S. Rapid recovery of hypogonadism in male patients with end stage renal disease after renal transplantation. Endocrine. 60(1):159–66.
19.
Leusen R, AE M. Cyclical changes in serum thyroid hormone concentrations related to hemodialysis: movement of hormone into and out of the extravascular space as a possible mechanism. Clin Nephrol. 18(4):193–9.
20.
21.
Mahajan R, Sobti S, Pruthi N, Mahajan M. Hypogonadism in chronic kidney disease patients. Indian Journal of Endocrinology and Metabolism. 17(5):840–4.
22.
Puthenveettil N, Calabrese G, Giglio G, Santoro D. Association of testosterone levels with clinical outcomes in patients with end-stage kidney disease: A systematic review and meta-analysis. J Endocrinol Invest. 44(3):471–85.
23.
Choi Y, Lee SW, Han JW, Kim W, Lee KS. Association between testosterone levels and all-cause mortality in men with end-stage renal disease: A systematic review and meta-analysis. Andrology. 8(3):672–80.
24.
Arver S, Lundin J, Rosenlund J. Testosterone levels and erythropoiesis in men with end-stage renal disease. Nephrol Dial Transplant. 14(1):61–6.
25.
S B, GR C. Testosterone therapy in men with testosterone deficiency: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 103(5):1715–44.
26.
Betz M, Akgul A, Azhar G, Gupta K. Pathophysiology of hypogonadism in end stage renal disease. Journal of Clinical Medicine. 9(12).
27.
Dunkel L, Raivio T, Laine J, Holmberg C. Circulating luteinizing hormone receptor inhibitor(s) in boys with chronic renal failure. Kidney International. 51(3):777–84.
28.
D G, D S. Greenspan’s Basic and Clinical Endocrinology.
29.
Edey MM. Male Sexual Dysfunction and Chronic Kidney Disease. Frontiers in medicine. 4:32–32.
30.
Meuwese CL, Stenvinkel P, Dekker FW, Carrero JJ. Monitoring of inflammation in patients on dialysis: forewarned is forearmed. Nat Rev Nephrol. 7(3):166–76.
31.
S R, JJ C. Endocrine alterations and cardiovascular risk in CKD: is there a link? Nefrologia. 33(2):181–7.
32.
Fukata J, Imura H, Nakao K. Cytokines as mediators in the regulation of the hypothalamic-pituitary-adrenocortical function. J Endocrinol Invest. 17(2):141–55.
33.
Carrero JJ, Kyriazis J, Sonmez A, Tzanakis I, Qureshi AR, Stenvinkel P, et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clinical journal of the American Society of Nephrology : CJASN. 7(2):207–15.
34.
A M, NS M. Hyperprolactinemia. J Hum Reprod Sci. 6(3):168–75.
35.
Gómez F, Cueva R, Wauters JP, Lemarchand-Béraud T. Endocrine abnormalities in patients undergoing long-term hemodialysis. The role of prolactin. Am J Med. 68(4):522–30.
36.
Wallaschofski H, Lohmann T, Hild E, Kobsar A, Siegemund A, Spilcke-Liss E, et al. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost. 96(1):38–44.
37.
Corona G, Rastrelli G, Boddi V, Monami M, Melani C, Balzi D, et al. Prolactin levels independently predict major cardiovascular events in patients with erectile dysfunction. Int J Androl. 34(3):217–24.
38.
Iglesias P, Carrero JJ, Díez JJ. Gonadal dysfunction in men with chronic kidney disease: clinical features, prognostic implications and therapeutic options. J Nephrol. 25(1):31–42.
39.
Holley JL. The hypothalamic-pituitary axis in men and women with chronic kidney disease. Adv Chronic Kidney Dis. 11(4):337–41.
40.
Lim VS, Kathpalia SC, Henriquez C. Endocrine abnormalities associated with chronic renal failure. Med Clin North Am. 62(6):1341–61.
41.
Mitchell R, Bauerfeld C, Schaefer F, Schärer K, Robertson WR. Less acidic forms of luteinizing hormone are associated with lower testosterone secretion in men on haemodialysis treatment. Clinical Endocrinology. 41(1):65–73.
42.
Yi S, Selvin E, Rohrmann S, Basaria S, Menke A, Rifai N, et al. Endogenous sex steroid hormones and measures of chronic kidney disease (CKD) in a nationally representative sample of men. Clin Endocrinol (Oxf. 71(2):246–52.
43.
JJ C, P S. The vulnerable man: impact of testosterone deficiency on the uraemic phenotype. Nephrol Dial Transplant. 27(11):4030–41.
44.
Carrero JJ, Qureshi AR, Nakashima A, Arver S, Parini P, Lindholm B, et al. Prevalence and clinical implications of testosterone deficiency in men with end-stage renal disease. Nephrol Dial Transplant. 26(1):184–90.
45.
Yilmaz MI, Sonmez A, Qureshi AR, Saglam M, Stenvinkel P, Yaman H, et al. Endogenous testosterone, endothelial dysfunction, and cardiovascular events in men with nondialysis chronic kidney disease. Clin J Am Soc Nephrol. 6(7):1617–25.
46.
Corrales JJ, Almeida M, Burgo R, Mories MT, Miralles JM, Orfao A. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol. 189(3):595–604.
47.
Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P. Low triiodothyronine and survival in end-stage renal disease. Kidney International. 70(3):523–8.
48.
Chonchol M, Lippi G, Salvagno G, Zoppini G, Muggeo M, Targher G. Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clinical journal of the American Society of Nephrology : CJASN. 3(5):1296–300.
I K, K O. Thyroid hormone and the cardiovascular system. N Engl J Med. 344(7):501–9.
51.
Alsaran K, Sabry A, Alshahhat H, Babgy E, Alzahrani F. Free thyroxine, free triiodothyronine and thyroid-stimulating hormone before and after hemodialysis in Saudi patients with end-stage renal disease: is there any difference? Saudi J Kidney Dis Transpl. 22(5):917–21.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
